Podcasts about principal investigators

Marco Damiani, Chief Executive Officer of AHRC New York City (AHRC NYC), joins the DEP RRTC's Let's Get to Work podcast hosted by Dr. Peter Blanck, University Professor and Chairman of the Burton Blatt Institute at Syracuse University and Principal Investigator of the DEP RRTC. Drawing on decades of experience supporting people with disabilities, Marco discusses his journey from working as a direct support professional to leading one of the largest organizations supporting people with intellectual and developmental disabilities in the U.S. He highlights the movement from institutionalization to community-based supports and services and the importance of self-advocacy, self-determination, and Supported Decision-Making. Marco and Peter also emphasize employment as a way to advance independence and community participation. Using AHRC NYC's nationally recognized initiatives as examples, they show how meaningful, competitive work benefits people with disabilities, employers, communities, and the broader economy.

Dr. Purvi Sevak, Senior Director of Mathematica's Disability Practice, joins the DEP RRTC's Let's Get to Work podcast hosted by Dr. Peter Blanck, University Professor and Chairman of the Burton Blatt Institute at Syracuse University and Principal Investigator of the DEP RRTC. Dr. Sevak discusses her path from an undergraduate student studying health policy to her work at Mathematica, the evolution and importance of disability employment policy, and her research with the DEP RRTC examining how local infrastructure affects employment opportunities for people with disabilities. Drawing on both professional and personal experiences, Dr. Sevak highlights the importance of disability employment policy to the broader economy. “Making sure that everyone who wants to work can work and contribute is important,” she states. “If people with disabilities are employed and earning more than they could be making on SSI, they're going to be spending more money and just contributing to the local economy, buying more things, renting apartments.”

Lindy Elkins-Tanton, Principal Investigator of Psyche, joins Jake and Anthony to talk about Leadership on big NASA missions in her new book Mission Ready. Topics Off-Nominal - YouTube Episode 244 - Helen from Everywhere (with Lindy Elkins-Tanton) - YouTube Mission Ready by Lindy Elkins-Tanton | Hachette Book Group NASA's Psyche Mission Aces Mars Flyby, Targets Metal-Rich Asteroid | NASA Jet Propulsion Laboratory (JPL) Psyche Mission Gallery - Images & Videos | Psyche Mission Psyche IRB (PDF) Follow Off-Nominal Subscribe to the show! - Off-Nominal Support the show, join the Discord Off-Nominal (@offnom) / Twitter Off-Nominal (@offnom@spacey.space) - Spacey Space Follow Jake WeMartians Podcast - Follow Humanity's Journey to Mars WeMartians Podcast (@We_Martians) | Twitter Jake Robins (@JakeOnOrbit) | Twitter Jake Robins (@JakeOnOrbit@spacey.space) - Spacey Space Follow Anthony Main Engine Cut Off Main Engine Cut Off (@WeHaveMECO) | Twitter Main Engine Cut Off (@meco@spacey.space) - Spacey Space Anthony Colangelo (@acolangelo) | Twitter Anthony Colangelo (@acolangelo@jawns.club) - jawns.club

This episode of the Mind the Kids podcast features Dr. Joanne Park, clinical psychologist and Principal Investigator of the Parenting Resilient Kids (Park) Lab at Mount Royal University, Canada. Hosted by Clara Faria, the conversation explores emerging research on “climate worry” in early adolescence, drawing on Dr. Park's recent publication in Child and Adolescent Mental Health.Dr. Park examines whether concerns about climate change represent a distinct psychological construct or are simply an extension of generalised anxiety. The discussion unpacks the difference between affective climate worry—emotional responses to climate change—and cognitive climate worry, which reflects more developed fears about future impact. Importantly, the findings suggest that climate worry is not only common among younger adolescents but may also have unique associations with wellbeing, independent of general anxiety.The episode also highlights key developmental, social, and gender-related factors shaping how young people experience climate-related distress. Dr. Park discusses why girls and gender-diverse adolescents may report higher levels of climate worry, and considers how clinicians, educators, and parents can respond without over-pathologising what may be a rational reaction to the climate crisis.This conversation is essential listening for clinicians, researchers, and educators interested in child and adolescent mental health, particularly those working with anxiety, emotional development, and the psychological impact of global challenges. It also offers practical insight into how to support young people in managing climate-related concerns through adaptive coping and resilience-building strategies.Read the CAMH journal paper ‘Prevalence, conceptual distinctiveness, and cross-sectional correlates of climate worry in Canadian adolescents' - https://doi.org/10.1111/camh.70076Joanne L. Park, Audrey-Ann Deneault, Brae Anne McArthur, Suzanne Tough, Sheri MadiganFirst published: 18 February 2026Get a free CPD/CME certificate for listening to this podcast by registering for a FREE ACAMH Learn account at https://bit.ly/4fF4BBWVisit https://www.acamh.orgFacebook and LinkedIn search / ACAMHInstagram https://www.instagram.com/assoc.camhBluesky https://bsky.app/profile/acamh.bsky.socialX https://x.com/acamh

In episode 78 of Going anti-Viral, Dr Rajesh T. Gandhi joins host Dr Michael Saag to discuss the process of guidelines development. Dr Gandhi is a Professor of Medicine at Harvard Medical School and Principal Investigator and Co-Director of the Harvard University Center for AIDS Research (CFAR). Dr Gandhi is the Vice-Chair of the ACTG, Vice-Chair of the Infectious Diseases Society of America COVID-19 Treatment Guidelines Panel, Chair of the International Antiviral Society-USA Panel on Antiretroviral Drugs for Treatment and Prevention of HIV in Adults, and the Lead Editor for Infectious Diseases, NEJM Clinician. Dr Gandhi and Dr Saag explore the intricate process of developing HIV treatment guidelines, including evidence review, panel selection, and updates on new topics like transgender care and substance use disorders. They discuss how guidelines are created, their impact on clinical practice, and future directions in HIV care.0:00 – Introduction 1:54 – The purpose and impact of guidelines4:00 – Panel composition and selection process6:00 – Guideline structure and key updates12:34 – Emerging topics: transgender care and transplant medicine14:31 – Substance use disorders and treatment innovations16:03 – Evidence-based recommendations and their strength22:07 – Guidelines development process and team dynamics24:42 – Living guidelines versus published documents28:41 – Closing thoughts and future directionsResources: Going-anti-Viral: Episode 32 - Update on the New Antiretroviral Therapy Guidelines - Dr Rajesh GandhiYouTube:  https://youtu.be/G7FQTInz-dY Apple Podcasts:  https://podcasts.apple.com/us/podcast/episode-32-update-on-the-new-antiretroviral-therapy/id1713226144?i=1000678818027 __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections.Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

In this episode of HPNA Palliative Perspective, we're joined by Betty Ferrell—Editor of the Journal of Hospice & Palliative Nursing (JHPN), nurse, and internationally recognized researcher. As the leader of the End-of-Life Nursing Education Consortium, she brings a unique perspective shaped by decades of connection with hospice and palliative care nurses across the U.S. and around the world.  Now in her 49th year in nursing—beginning in oncology and entering hospice as it emerged in the United States—Dr. Ferrell reflects on the remarkable growth of the field and where we stand today.  At the heart of this conversation is the idea of a “professional home.” Drawing on the foundational work of pioneers like Florence Wald and Cicely Saunders, she highlights the enduring importance of interprofessional, whole-person care—and the need to stay grounded in those values as the field evolves.  In a time that can feel complex and demanding, this episode offers a clear message: you don't have to do this work alone. Finding your people, building community, and staying connected—through colleagues and organizations like the Hospice and Palliative Nurses Association—are essential to sustaining both practice and purpose.  A thoughtful and reassuring conversation about belonging, connection, and the future of hospice and palliative nursing.      Betty Ferrell, RN, PhD, MA, CHPN®, FAAN, FPCN® Betty Ferrell, RN, PhD, MA, CHPN®, FAAN, FPCN® has been in nursing for 48 years and has focused her clinical expertise and research in pain management, quality of life, and palliative care. Dr. Ferrell is the Director of Nursing Research & Education and a Professor at the City of Hope Medical Center in Duarte, California. She is a Fellow of the American Academy of Nursing and she has over 500 publications in peer-reviewed journals and texts. She is Principal Investigator of the “End-of-Life Nursing Education Consortium (ELNEC)” project. She directs several other funded projects related to palliative care in cancer centers and QOL issues. Dr. Ferrell was Co-Chairperson of the National Consensus Project for Quality Palliative Care. Dr. Ferrell completed a Masters degree in Theology, Ethics and Culture from Claremont Graduate University in 2007. She has authored 12 books including the Oxford Textbook of Palliative Nursing (5th Edition, 2019) published by Oxford University Press. She is co-author of the text, The Nature of Suffering and the Goals of Nursing published by Oxford University Press (2nd Ed, 2023) and Making Health Care Whole: Integrating Spirituality into Patient Care (Templeton Press, 2010). In 2013 Dr. Ferrell was named one of the 30 Visionaries in the field by the American Academy of Hospice and Palliative Medicine. In 2019 she was elected a member of the National Academy of Medicine. In 2021 Dr. Ferrell received the Oncology Nursing Society Lifetime Achievement Award and she was inducted as a “Living Legend” by the American Academy of Nursing   Brett Snodgrass, DNP, FNP-C, ACHPN®, FAANP Dr. Brett Snodgrass has been a registered nurse for 28 years and a Family Nurse Practitioner for 18 years, practicing in multiple settings, including family practice, urgent care, emergency departments, administration, chronic pain and palliative medicine. She is currently the Operations Director for Palliative Medicine at Baptist Health Systems in Memphis, TN. She is board certified with the American Academy of Nurse Practitioners. She is also a Fellow of the American Association of Nurse Practitioners and an Advanced Certified Hospice and Palliative Nurse. She completed a Doctorate of Nursing Practice at the University of Alabama – Huntsville. She is a nationally recognized nurse practitioner speaker and teacher. Brett is a chronic pain expert, working for more than 20 years with chronic pain and palliative patients in a variety of settings. She is honored to be the HPNA 2025 podcast host. She is married with two daughters, two son in laws, one grandson, and now an empty nest cat. She and her family are actively involved in their church and she is an avid reader.

Photo by Sergiu Vălenaș on Unsplash Wars and other life circumstances can result in children being orphaned and neglected. Around the world, including in our own community, grandparents are becoming caregivers for their grandchildren, but often with little support. Someone who has been studying this issue is Dr. Schola Matovu, a gerontological nurse scientist, Assistant Professor and Director of Global Learning and Engagement at the University of Utah College of Nursing, where she also serves as the Principal Investigator for the Matovu Research Lab. She is a Fellow in the Betty Irene Moore Fellowship for Nurse Leaders and Innovators. HealthCetera host Diana J. Mason, PhD, RN, talked with Dr. Matovu about her work on grandparents as caregivers for their grandchildren. This interview first aired on HealthCetera in the Catskills on WIOX Radio on April 29, 2026. The post Grandparents Becoming Caregivers appeared first on HealthCetera.

Leading Irish neuroimmunologist Prof. Denise Fitzgerald has been awarded €6.26 million Research Professorship funding from Research Ireland to investigate ways that ageing affects how the immune system helps repair brain tissue in illnesses such as Multiple Sclerosis (MS). The funding means that over the next five years, Prof. Fitzgerald – who has, until now, been based exclusively in Queen's University Belfast – will lead a research team of ten based in Trinity College Dublin and partnering with FutureNeuro Research Ireland Centre for Translational Brain Science, St James's Hospital and Beaumont Hospital to discover why our immune cells become less able to coax brain stem cells to repair damage as we age. This research combines immunology, neuroscience and regenerative biology to tackle this complex problem. Prof. Fitzgerald said: "This ambitious programme of research will uncover new insights into fundamental changes in the older immune system that has a knock-on effect on brain repair. This new knowledge can then be used to develop pioneering regenerative treatment for MS and other neurological conditions. To speed this up, we are embedding research into new clinical trials led by consultant neurologist, Hugh Kearney. "This will increase the opportunities for people with MS in Ireland to access experimental treatments early, as well as to co-produce research with us as key public members of the research programme. Through this neuroimmunology research programme we will train the next generation of scientists, doctors and health professionals, side-by-side, in partnership with the public." Commenting on the announcement, Dr Diarmuid O'Brien, CEO of Research Ireland commented: "Research Ireland is pleased to support Prof. Fitzgerald's critically important work over the next five years, with the investment facilitating an additional 11 research positions, comprising postdocs, PhDs, research assistants and senior research fellows. Funding excellent research talent is a key part of our recently launched strategy, as is addressing Ireland's opportunities and challenges in areas such as public health. I look forward to seeing the outputs and impact of Prof. Fitzgerald's endeavours over the coming years." Through this appointment, Prof. Fitzgerald will divide her role between Trinity College Dublin and Queen's University Belfast, promoting all-island collaboration across neuroimmunology and other research areas. She will be an investigator at FutureNeuro, the RCSI-based Research Ireland Centre that aims to translate breakthroughs in understanding of brain structure and function to transform the patient journey for people with neurological diseases. She also brings extensive international collaboration with world-leading experts at Cambridge University, University College London, the University of Toronto, the Institute of Neuroscience – Alicante, the Wellcome Sanger Institute and Maynooth University. Prof. Colin Doherty, head of the School of Medicine in Trinity and a Principal Investigator with FutureNeuro said: "I have known Denise for some time and have marvelled at the quality of her research into one of the great and challenging areas of medical science. We are delighted that she will be leading a team here in Trinity while retaining her links with Queen's, strengthening all-island collaboration in neuroimmunology and creating exciting new opportunities across the wider FutureNeuro research network." See more stories here. Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find...

Looking for the latest research on epidermolysis bullosa (EB)?  We've got just the expert! This week, we're joined by Dr. Mercedes Gonzalez as she jumps into her team's pediatric dermatology research and their look at epidermolysis bullosa. Listen in as she discusses the historic progress in EB treatments and what that means for patients. Each Thursday, join Dr. Raja and Dr. Hadar, board-certified dermatologists, as they share the latest evidence-based research in integrative dermatology. For access to CE/CME courses, become a member at LearnSkin.com. Dr. Mercedes E. Gonzalez is a board-certified pediatric dermatologist at DERM360 and Medical Director of Pediatric Skin Research in Miami, Florida. She serves as Assistant Professor of Dermatology at Florida International University Herbert Wertheim College of Medicine and the University of Miami Miller School of Medicine. A graduate of Emory University and Rutgers–New Jersey Medical School, she completed her pediatrics residency at Columbia University and dermatology and pediatric dermatology training at NYU. Dr. Gonzalez is Principal Investigator on multiple clinical trials, co-editor of three dermatology textbooks, and a Director on the American Board of Dermatology, where she chairs the several committees. Sponsored by: Chiesi Medical AffairsVisit Chiesi Medical Affairs website for more information.

A large-scale analysis of Grokipedia, the world's first AI-written encyclopedia, has found that while many Grokipedia articles closely resemble their Wikipedia counterparts, a substantial subset diverged markedly in style, sourcing, and political leaning. Conducted by researchers at Trinity College Dublin and Technological University Dublin, the study compared nearly 18,000 of the most-edited English-language Wikipedia pages with articles on the same topic on the new Grokipedia platform. The study is the largest academic analysis of Grokipedia since it was launched by Elon Musk last October with a promise that the AI-written encyclopedia systematically "fixes" left-leaning biases alleged to exist in the widely used online encyclopedia Wikipedia. Wikipedia's content is written and maintained by volunteer editors, while Grokipedia is an AI-generated encyclopedia using the xAI's Grok large language model. What did the study find? Using computational text analysis and machine learning methods, the team analysed articles on the same topic across Wikipedia and Grokipedia. Selection of topics was based on Wikipedia's most-edited English-language pages. The team compared differences in writing style, structure, and the political orientation of external sources referenced in the paired articles. The researchers found a profound split – while many Grokipedia articles closely mirror Wikipedia, a substantial proportion (66%) of the 18,000 analysed are more extensively rewritten – they are longer, more complex, and rely on fewer references. As a whole, articles on Grokipedia show similar political leaning to those on Wikipedia, drawing on left-leaning news sources. However, when it comes to the politically and culturally sensitive topics of religion, history, literature and art, Grokipedia shows a consistent shift toward referencing more right-leaning news sources compared to Wikipedia. The study analysed Wikipedia's most-edited English-language pages, a selection that likely overrepresents high-profile and contentious topics. That said the study, according to the authors, provides useful evidence of emerging differences between AI-generated and human-edited encyclopedic knowledge systems. Details of the research, conducted at the joint Centre for Sociology of Humans and Machines (SOHAM) in Trinity and TU Dublin, have been published in the peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS). What is the impact of this research? Lead author of the study, Saeedeh Mohammadi, PhD candidate at SOHAM and Research Ireland's Centre for Research Training in Foundations of Data Science said: "Online encyclopedias are central to public knowledge. They are also being used to train future generations of large language models. Our findings raise important questions about how public knowledge is produce, reproduced, verified, and governed. "Unlike Wikipedia, where biases are visible and contested through human editing, AI-generated systems operate largely opaquely. This means shifts in perspective or sourcing may occur without clear accountability or editorial oversight. Simply put AI generation does not remove bias – it changes how and where bias enters the system, often making it less visible." Professor Taha Yasseri Director of SOHAM and Principal Investigator of the study said: "Rather than systematically 'correcting' Wikipedia's alleged biases, as claimed when first launched, our findings suggest that AI-generated encyclopedias such as Grokipedia selectively reshape existing knowledge. This creates a patchwork system in which some content is copied, while other content is reinterpreted in ways that are less transparent and harder to scrutinise." "There is a dire need for transparency, oversight, and regulation in this space. Our information landscape is changing rapidly. We have already seen how the lack of editorial responsibility on social media platforms has enabled the generation and circulation of misinformation and ...

In this episode in the Eco-Justice and Climate Action Mini Series, we sat down with four members of the Climate Education and Teacher Education (CETE) team, which is based at the University of Northern British Columbia. Authors of “Mapping Climate Change Education: Reflections from an Education Design-Based Research Project from Northern British Columbia, Canada,” the CETE team created this project in response to the 2022 Association of Canadian Deans of Education report titled "Accord on Education for a Sustainable Future," which underscored urgency for climate change education. Join us for another great episode exploring the stories behind this collaborative and exciting action research project!To begin, our hosts Joe and Blane introduce the CETE team and the article that brought them together [00:00]. This leads into the origin story of the initiative and discussion of their team dynamics, which lead to a shared commitment to curriculum reform and a signature pedagogy built around people, place, and land [1:57]. The conversation then explores the co-creation process at the heart of the project, from building a national design team to running iterative workshop series across northern British Columbia, reflecting on how listening to teachers and communities continuously reshaped the project's direction [7:50]. From there, the team reflects on the iterative, cyclic nature of their design-based research, and the challenges of working within research frameworks that don't always honour more-than-human species and Indigenous ways of knowing [17:03]. We move to a discussion about the tension between theory and action, and between local focus and global relevance, focusing on how grounding the work in northern land, language, and Indigenous knowledge has proven to be both their most impactful contribution and a transferable model for others [22:23]. The team closes by sharing where the project stands today, and our hosts wrap up by honouring the messiness of action research as a defining strength of the journey, not a flaw [34:04].Thank you Hartley, Christine, Alexander and Glen for sharing your time and work with us.Thank you to our listeners for tuning in to this episode of the Action Research Podcast, created by Adam Stieglitz, Joe Levitan, Shikha Diwakar, Cory Legassic, and Vanessa Gold.Produced by Shikha Diwakar and Vanja Lugonjic.Subscribe to our podcast on most major podcast distribution platforms, including Spotify and Apple Podcasts.How have you found yourself in the world of action research? Want to be interviewed or share one of your projects? Get in touch with us.Resources: CETE Research PageBiographies: Hartley Banack, University of Northern British ColumbiaDr. Hartley Banack is an Associate Professor in the School of Education at UNBC and Principal Investigator for the CETE research program since 2022. Banack is a curriculum theorist, qualitative researcher, and teacher. He has years of experience as an outdoor environmental educator and scholar. His scholarship appears in Teachers and Teaching (Banack and Tembrevilla, 2024), Children's Geographies (Banack and Berger, 2020), and Critical Education (Banack, 2018). Banack holds a Ph.D., M.A., and B.Ed. in environmental education, all from Simon Fraser University, along with a B.Sc. from Trent University.Christine Ho Younghusband, University of Northern British ColumbiaDr. Christine Ho Younghusband is an Assistant Professor in the School of Education at UNBC. Dr. Ho Younghusband is a founding CETE Co-Investigator. Her research focuses on teacher professional learning, identity development, and mathematics education. She has published on e-portfolios and identity (Younghusband, 2021) and out-of-field teaching (Younghusband, 2017). Dr. Ho Younghusband holds an Ed.D. and M.Ed. from Simon Fraser University, and B.Ed. and B.Sc. from the University of British Columbia.Alexander Lautensach, University of Northern British ColumbiaDr. Alexander Lautensach is an Adjunct Professor in the School of Education at UNBC. Lautensach is a founding CETE Co-Investigator. He holds five degrees in the areas of biology, science education, and philosophy, including a doctorate in environmental ethics education from the University of Otago, New Zealand. Lautensach has written two books on sustainability education and climate change and co-published the first open-access textbook on human security.Glen Thielmann, University of Northern British ColumbiaGlen Thielmann is a Lecturer in the UNBC School of Education. He is a founding member of the CETE Research Team. He is a master Social Studies teacher with leadership in curriculum, instruction, and professional & resource development in B.C. K-12 schools. In 2017, Glen received a Governor General's History Award for excellence in Teaching. In 2022, Glen received a Teacher Educator Award from the Association of BC Deans of Education.--This episode is part of our Eco-justice and Climate Action Series. Authors from journal articles in a Special Issue of the Canadian Journal for Action Research hop behind the mic and share the inspirations, process, and findings from their projects. Join Joe Levitan, Shikha Diwakar and special guest host Blane Harvey, as they interview an inspiring group of researchers, educators, organizers, and more, navigating the process of action research.

Co-hosts Ryan Piansky, a graduate student and patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Dr. Chukwuemeka Oko, MD, MBA, on clinical trials. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:49] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of Education Partners GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:13] Holly introduces today's topic — clinical trials — and today's guest, Dr. Chukwuemeka Oko, a Clinical Research and Medical Affairs Professional supporting Duke University Hospital's Department of Gastroenterology and Transplant Hepatology.   [1:33] Dr. Oko explains that he is sharing general, educational information from his perspective and experience, not speaking on behalf of Duke University, nor any industry sponsor, nor any company he has worked for.   [1:50] Dr. Oko's goal today is to help the listeners feel clearer, more confident, and more in control when they are thinking about clinical research.   [2:29] Dr. Oko's work sits mainly at the intersection of clinical research and medical affairs. He helps translate evolving science into practical, patient-centered decisions.   [2:40] From an academic standpoint, he supports clinical trials and evidence generation from feasibility through education.   [2:49] Dr. Oko also engages investigators and thought leaders from industry sponsors in scientific exchanges that lead to insights, study design, and real-world care pathways.   [3:03] Dr. Oko had two reasons to study eosinophilic esophagitis and eosinophilic disease. The first is the patient journey and biology.   [3:11] On the patient side, many people spend a long time seeking answers. Sometimes they feel dismissed before they get a clear diagnosis and a plan that fits their life.   [3:24] On the biology side, eosinophilic disease teaches us a lot about how our immune signals can drive information differently across tissues like the esophagus and airways.   [3:40] Dr. Oko supported an EoE study experience with an industry sponsor in the past. The best research doesn't just test; it helps patients and clinicians make clearer decisions.   [4:12] Dr. Oko explains that a clinical trial is a carefully designed, carefully crafted study in people that answers specific medical questions, most often about safety, effectiveness, or dosing of the study drug or how a treatment should be used.   [4:32] A key structure of a study is a written protocol where safety monitoring is in place, and the defined outcome or results are very reliable. The FDA always oversees clinical trials in the U.S.    [4:44] Dr. Oko often describes a trial as a highly-monitored learning system. It's how medicine moves from "We think this might help" to "We know what helps, for whom, and also at what risk."   [5:09] Dr. Oko says clinical trials usually study what improves patient outcomes, for whom, and at what risk, using methods that we can trust. Trials may evaluate new medicines, devices, dosage strategies, or even procedures.   [5:31] Clinical trials can also study non-drug approaches such as diet interventions, symptom tracking, monitoring tools, and education strategies.   [5:44] Many trials have also included biomarkers, or signals in the blood or tissue, helping to support an EoE diagnosis so that the patients can get treated in an early and effective manner.   [6:36] Dr. Oko says patients sometimes ask him if they are guinea pigs. In reality, trials are heavily regulated and closely monitored, with strict safety reporting requirements. Participants are not guinea pigs.   [7:06] Dr. Oko also hears patients ask if they are "stuck" once they join the clinical trial. No, a trial is a completely voluntary participation, and they can withdraw at any time.   [7:25] Other patients ask if trials are only for people who are out of options. Many trials are designed for earlier stages, especially when the goal is to prevent complications or reduce steroid exposure.   [7:46] The last question Dr. Oko hears a lot is "Will I be in the placebo group?" He says it's an understandable fear. They are asking if they will go untreated in the placebo group.   [8:29] In many trials, a placebo is not the same as "no care". Often, the participants continue the standard-of-care treatment, and the study drug or placebo is added to the standard-of-care treatment.   [8:45] Trials typically involve symptom monitoring and a plan for what happens if the symptoms worsen. There are exit criteria.   [9:01] From the pharmaceutical side, it's the end of treatment once you decide to voluntarily exit the study.   [9:10] Dr. Oko's advice is, if you participate, ask the study team physicians to explain in plain language what you'll receive, what you can continue, and what happens if you flare up. Clear answers are always a part of ethical research.   [10:33] Holly asks what it means to participate in a Phase 1, Phase 2, or Phase 3 trial. Dr. Oko says a Phase 1 trial is focused mostly on the safety and the dosing regimen. It's usually a small group of five to 100 or so.   [10:52] A Phase 2 trial always looks for the drug's effectiveness and continues monitoring safety. It's usually a group of 100 to 300 subjects. They look for meaningful signals of the outcomes derived from the trial.   [11:10] A Phase 3 trial is usually large. It's multi-centered. It's called a complementary study. It involves thousands of patients. It can even be across nations and states.   [11:26] This is where they compare new interventions against a placebo or against a standard of treatment to provide clinical benefits and support for regulatory approval.    [12:03] Participating in any phase of a trial includes fitting the eligibility criteria of inclusion for that particular phase. If you are a good match, you can be in either a Phase 1, Phase 2, or Phase 3 trial.   [12:52] Holly says she knows that a lot of people with EoE or EGIDs are very curious about trials and how to participate in them.   [13:00] Ryan says we have a very active patient community, and everyone's looking for ways to get involved in research and new diagnostics or medications to improve their own outcomes and help everyone else.   [13:35] Dr. Oko says the benefits of participating in a clinical trial include access to potentially disease-modifying therapies years before they reach the market.   [13:47] Another benefit is extraordinarily close medical monitoring. When you're in a clinical trial, you have more frequent visits and more frequent labs than usual.   [14:01] Endoscopies are out of the normal standard of care, but will be more frequent than normal to analyze the efficacy of the study drug.   [14:11] Dr. Oko says one of the risks is the unknown side effects the study drug comes with, because we are still understanding the biology.   [14:21] The time commitment for visits can be more than typical for a patient, especially if there is a long travel time involved. Patients may arrive at 7:00 or 8:00 a.m. They may need to find a place to live nearby, depending on the pace of the trial.   [14:57] Holly lives in Maine, and a lot of the trials are in Boston. It's a lot of travel. For people with any kind of chronic illness, all we think about is money. Holly asks if people pay to be part of a clinical trial.   [15:25] Dr. Oko states that the patients do not have to pay anything to be part of a clinical trial. Patients do get compensated by the trial sponsor for travel, accommodation, parking, and a meal for the days they are onsite.   [16:33] Dr. Oko says that patients tend to bring up insurance. It is a misconception that the study will pay for their standard-of-care medication during the study. Patients need to ask the study team what insurance will pay for and what the study will pay for.   [16:59] Dr. Oko says the insurance usually covers the regular standard-of-treatment, but any other additional treatment, procedures, and visits are all covered by the study sponsor.    [17:29] The study sponsor may ask for an endoscopy to be done six months before the study to determine eligibility for the study. If it is done within a year, the study sponsor will determine if you are qualified. That is part of the eligibility criteria in some cases.   [18:26] Dr. Oko tells patients to always ask questions, like what the schedule of events is in the clinical trial.   [18:35] The schedule of events tells you how many visits are required for you to be part of this study. They will list the activities to be done. They will list the labs you will need at what week. They will list when you need endoscopies, at week one and later.   [19:05] If you exit from the study, if you don't want to participate anymore, you are still required to come on site just to make sure that you are in good shape. Those are called formal visits.   [10:29] Dr. Oko explains that formal visits are necessary for the patient's safety and to make sure that the data points collected in the study will be effective.   [20:01] Patients enrolling in a clinical trial can also ask about the known risks of the symptom monitoring plan. They can ask what is covered and what is not covered by insurance, and what will be considered out of pocket.   [20:20] If patients are in the placebo group, what will happen if symptoms worsen? In the protocol, there is always a rescue plan. If a symptom flares up, the Principal Investigator carries out the rescue plan.   [20:58] The study team is available on a 24/7 hotline. The questions you ask are very important. No question is too small to ask. Every question and every symptom you report is important. You can withdraw at any time, and there is always a follow-up.   [22:19] Dr. Oko says the trial data that has already been collected from part of our eosinophilic studies has led to various FDA approvals of the biologics. We are working  to try to transform EoE from a steroid-dependent or diet-only disease into a position of long-term control.   [22:37] Trial findings have shaped care, expanding evidence-based options, clarifying which patients benefit the most, and improving how we measure our outcomes, the symptoms, and quality of life, as measured by patients' quality-of-life surveys.   [23:06] Quality-of-life surveys are very important for the study team. They help to measure safety, too. The evidence generated from this data leads to insights and improves study design, protocol design, and ultimately, improves patient care.   [23:40] Ryan says the community is interested in clinical trials because they benefit patients, researchers, and clinicians. We're thankful for the clinicians and researchers putting in all the work to make these clinical trials happen.   [24:01] Ryan adds, we're also thankful for the patients who are interested in these trials. For patients who are looking to participate, how can they find clinical trials to participate in and join?   [24:15] Dr. Oko says people can find the website ClinicalTrials.gov. It's an important tool in looking for various clinical research. Scientists are recruiting at a given time. You can use the Advanced Search option to narrow the search by state and criteria.   [24:54] You can always discuss clinical trials with your primary care physicians. You can look for major academic medical centers. Most of them always have clinical research studies going on.   [25:07] Dr. Oko says APFED.org is a very good tool. It always maintains up-to-date trial listings and patient-friendly summaries where patients can read about the studies.   [25:30] Ryan says he's very appreciative of the mention of APFED. There is a link on APFED.org so people can find studies. There are clinical trials listed that people can research more and join.   [25:46] Holly asks Dr. Oko to share advice for listeners who are considering participating in a clinical trial. He shares, "I want each one of you to approach the decision with the same care you would with any major medical choice. Review the Informed Consent Form (ICF)."   [26:23] "The word informed means you should be informed. It's your right to get informed with every line, every detail. The Consent Form can be 30 pages long, but please just know that you are not in a rush to answer."   [26:43] "You can take the Consent Form and discuss it with your friends, your family, your primary care physician, your gastroenterologist, and your allergist and get more information."   [27:00] "When you join an interventional trial, or a registry, your contribution accelerates the science and benefits the entire eosinophilic community."   [27:12] "From my years of reviewing medical charts and supporting new recruitments, I feel patients feel most satisfied when they are fully informed and genuinely partnered with the study team. That's how I partner with the patients. I am always there to help."    [27:40] Ryan says that is great advice for patients, and hopefully, some of our listeners to this episode will go out there and look for clinical trials to participate in or ask their physicians, next time they're getting care.   [27:52] For patients who would like to know more about eosinophilic disorders, we encourage you to visit APFED.org and check out the links in the show notes below, specifically to research opportunities listed on APFED.org. [28:08] If you've been personally impacted by eosinophilic disorders and are interested in sharing your experiences, we encourage you to please check out APFED.org/shareyourstory.   [28:17] Ryan thanks Dr.Oko for joining us today. This was really helpful and insightful, and hopefully, we'll have many new patients interested in joining clinical trials. Dr. Oko thanks Ryan and Holly for having him on and thanks every listener who has joined us.   [28:33] Dr. Oko says it has been a genuine pleasure and privilege for him. He has spent years seeing patients, reviewing their charts, and hearing their stories. We see you, we hear you. Science is advancing rapidly and shaping outcomes. You are not alone.   [30:17] Holly thanks Dr. Oko for his research and clinical trials, and thanks APFED's Education Partners GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast Apfed.org apfed.org/specialist apfed.org/connections apfed.org/research/clinical-trials Duke University Hospital's Department of Gastroenterology Education Partners: This episode of APFED's podcast is brought to you thanks to the support of GSK, Sanofi, Regeneron, and Takeda.   Tweetables:   "Many people spend a long time seeking answers. Sometimes they feel dismissed before they get a clear diagnosis and a plan that fits their life." — Chukwuemeka Oko, MD, MBA   "On the biology side, eosinophilic disease teaches us a lot about how our immune signals can drive information differently across tissues like the esophagus and airways." — Chukwuemeka Oko, MD, MBA   "In many trials, a placebo is not the same as no care. Often, the participants continue the standard-of-care treatment, and the study drug or placebo is added to the standard-of-care treatment." — Chukwuemeka Oko, MD, MBA   "I tell patients to always ask questions, like what the schedule of events is in the clinical trial." — Chukwuemeka Oko, MD, MBA   "[If a patient exits the study], formal visits are necessary for the patient's safety and to make sure that the data points collected in the study will be effective." — Chukwuemeka Oko, MD, MBA   "From my years of reviewing medical charts and supporting new recruitments, I feel patients feel most satisfied when they are fully informed and genuinely partnered with the study team." — Chukwuemeka Oko, MD, MBA   Guest Bio: Chukwuemeka Oko, MD, MBA

Nadine Dijkstra is a Principal Investigator at the Institute of Neurology at UCL. Her research in Imaging Neuroscience explores how the brain generates mental images and differentiates them from actual perception. Utilizing neuroimaging, psychophysics, machine learning, and computational modeling, Dijkstra addresses fundamental questions about the overlap between perception and imagery.Recently, Dijkstra has been leading the Imagine Reality Lab at UCL's Department of Imaging Neuroscience, focusing on the intersection of imagination and reality. Dijkstra's 2023 paper in Nature Communications showed the brain evaluates images against a 'reality threshold' to distinguish between images and perception. Her work also investigates how changes in these neural processes could impact mental health.Check out our new series, Ideas for Our Time: https://youtu.be/nYS4FylZJ2QDon't hesitate to email us at podcast@iai.tv with your thoughts or questions on the episode!To witness such debates live buy tickets for our upcoming festival: https://howthelightgetsin.org/festivals/And visit our website for many more articles, videos, and podcasts like this one: https://iai.tv/You can find everything we referenced here: https://linktr.ee/philosophyforourtimesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Gugs Mhlungu talks to Jerome Singh, clinical public health professor and legal scholar, serving as Principal Investigator of SAGE and an Honorary Research Fellow at the University of KwaZulu-Natal about the growing threat of extreme heat and its impact on health, jobs, food security and nutrition. They also explore practical solutions, including creating cooling spaces, improving illness surveillance, and investing in greener, more climate-resilient communities through trees and accessible cooling infrastructure. Gugs Mhlungu gets you ready for the weekend each Saturday and Sunday morning on 702. She is your weekend wake-up companion, with all you need to know for your weekend. The topics Gugs covers range from lifestyle, family, health, and fitness to books, motoring, cooking, culture, and what is happening on the weekend in 702land. Thank you for listening to a podcast from 702 Weekend Breakfast with Gugs Mhlungu. Listen live on Primedia+ on Saturdays and Sundays from 06:00 and 10:00 (SA Time) to Weekend Breakfast with Gugs Mhlungu broadcast on 702 https://buff.ly/gk3y0Kj For more from the show go to https://buff.ly/u3Sf7Zy or find all the catch-up podcasts here https://buff.ly/BIXS7AL Subscribe to the 702 daily and weekly newsletters https://buff.ly/v5mfetc Follow us on social media: 702 on Facebook: https://www.facebook.com/TalkRadio702 702 on TikTok: https://www.tiktok.com/@talkradio702 702 on Instagram: https://www.instagram.com/talkradio702/ 702 on X: https://x.com/Radio702 702 on YouTube: https://www.youtube.com/@radio702See omnystudio.com/listener for privacy information.

Today we are talking to Dr. John “Kip” Kramer about neuropathic pain. Dr. Kramer is a Principal Investigator and Associate Director of Operations at the International Collaboration on Repair Discoveries or iCORD at the University of British Columbia. His research interests include: Neuropathic pain, anesthesiology, MRI, Outcome measures and clinical trials. In this discussion we cover... More info: https://u2fp.org/get-educated/curecast/episode-142.html

Dr. Robert Wagner, Senior Medical Director and Principal Investigator at CTI's Clinical Research Center, shares more about clinical trial operations at research sites.  Reflecting on nearly three decades in internal medicine and hospital‑based care, Dr. Wagner shares his path from patient care into clinical research, how that experience shapes his approach as an investigator, and why strong research sites are critical to trial quality and outcomes. The conversation also touches on the day‑to‑day realities of running trials and how site operations, technology, and patient‑centered practices continue to evolve. 01:00 His past experiences and current role as a Principal Investigator at CTI.03:00 How clinical experience shaped his transition into research.05:30 Daily responsibilities and the importance of sites.08:30 Technology, recruitment, and patient access.10:45 Guidance for physicians and patients; the future of clinical research.

Liz Horn, PhD, MBI, serves as Principal Investigator of Lyme Disease Biobank, a resource that provides much-needed blood, urine, and tissue samples to researchers studying Lyme disease and other tick-borne infections. She has spent more than 2 decades working with non-profit organizations to build research initiatives and collaborations with academia, other non-profits, and industry. Since 2020, she has served as a scientific advisor for the LymeX Diagnostics Prize, a public-private partnership between the U.S. Department of Health and Human Services (HHS) and the Steven & Alexandra Cohen Foundation. Liz is passionate about building resources to move research forward that help people, improve lives, and reduce suffering. She earned her doctorate in molecular pharmacology and cancer therapeutics from SUNY at Buffalo, was a National Library of Medicine fellow in biomedical informatics, and received her MBI from Oregon Health & Science University. 

S8 E2: Character Development w/Dr. Scott Seider and Dr. Shelby ClarkIn this episode, Gerald and Alexis spoke with Dr. Scott Seider and Dr. Shelby Clark on the topic of developing character, with a context of how to develop character within schools. We dive into the key insights and lessons from their research on the topic, found in their new book: Character Compass, Second Edition: Four Directions for Building Powerful School Culture and Student Success.In this episode we dive into some insightful discussions around how we can understand character development and how we support and expand these values to young people or within a community. Summary:How are character traits defined?How do schools prioritize certain character traits?How are character traits developed in schools?How do we engage young people in conversations about character?Scott Seider is an applied developmental psychologist studying how parents and educators support young people's identity and civic development. A professor at Boston College and former Boston Public Schools teacher, he is the author of several books, including Educating for Justice (2025) and Schooling for Critical Consciousness (2020).Shelby Clark, Ph.D. (she/her) is a Principal Investigator at Project Zero and Project Director with The Good Project. Her research focuses on developing intellectual, moral, and civic character in young people—especially curiosity, open-mindedness, and social responsibility. She holds a Ph.D. from Boston University and previously worked as a school counselor in St. Paul, MN.The ReidConnect-Ed Podcast is hosted by @AlexisAnnReid and Dr. Gerald Reid, produced by @CyberSoundRecordingStudios, and original music is written and recorded by Gerald Reid (www.Jerapy.com) @MusicJerapy.*Please note that different practitioners may have different opinions- this is our perspective and is intended to educate you on what may be possible.Show notes & Transcripts: https://reidconnect.com/reid-connect-ed-podcastBe Curious. Be Open. Be Well.#character #characterdevelopment #schools #teaching#leadership #education #youthdevelopment #positiveyouthdevelopment

A lifelong smoking ban in the UK has been agreed to - but only for people born after 2008. This means that anyone born on January 1st 2009 onwards will legally not be allowed to purchase tobacco…Is this something we should replicate here? Would it be possible?Joining Shane to discuss is Dr Frank Haughton, Principal Investigator at the HEALR Research Group in Technological University of the Shannon.

Iowa continues to rank among the highest in the nation for cancer incidence, and it's one of the few states in the country where rates are still rising. What's behind the numbers?In the latest episode, Dr. Andrew Nish is joined by Mary Charleton, a professor of Epidemiology and the Director and Principal Investigator at the State Health Registry of Iowa and the Iowa Cancer Registry to break down the Cancer in Iowa Report 2026 and what it means for Iowans.

The concept of domicide and its profound impact on Homs, Syria, is explored through the work and personal experiences of architect Ammar Azzouz. A research fellow at the University of Oxford, Dr. Azzouz discusses the deliberate destruction of homes, the trauma of exile, and his eventual return to his homeland. He examines how international attention frequently prioritizes the loss of ancient heritage sites, such as Palmyra, while often overlooking the intimate grief associated with the destruction of residential areas where people lived their daily lives. The discussion also delves into the slow violence of pre-war urban projects, like the "Homs Dream", which proposed demolishing parts of the historic old city for modern development, and how these top-down models continue to threaten the city's identity during current reconstruction efforts.   01:04 Introduction 01:35 Personal Memories of Home 05:00 The Architectural Identity of Homs 06:11 Exile and Return 10:51 Domicide vs. Urbicide 13:16 Slow Violence and the Homs Dream 17:18 The Politics of Reconstruction and Dubaization 21:04 Alternative Visions for Healing 33:00 Empowering the Next Generation 34:32 The Limitations of International Heritage Organizations 41:06 Highlighting Favorite Historical Sites   Dr. Ammar Azzouz is a British Academy Research Fellow at the School of Geography and the Environment, University of Oxford. Originally from Homs, Syria, he studied architecture before moving to the UK to complete his PhD. Since leaving Syria in 2011, he has not been able to return. Dr. Azzouz is the author of Domicide: Architecture, War and the Destruction of Home in Syria (2023, Bloomsbury), with a foreword by Lyse Doucet, the BBC's Chief International Correspondent. He is the Principal Investigator of the Slow Violence and the City research project, which explores the connection between violence and the built environment in both wartime and peacetime. His current research focuses on art and culture in exile, particularly within the Syrian diaspora. Dr. Azzouz has contributed to platforms such as The New York Times, The Guardian, and The New Statesman, and has been invited to speak at over 130 events worldwide, from Mexico and the US to Germany, the Netherlands, and Qatar.   Connect with Dr. Ammar Azzouz

Among the barriers faced by researchers who move abroad to develop their careers is a so-called “hidden curriculum,” says Sonali Majumdar, whose book, Thriving as an International Scientist, was published last year.Navigating these unwritten rules that cover social norms and cultural expectations, both in the lab and outside work, can feel particularly daunting to scientists who, like her, were born elsewhere, she adds. In addition, international scientists often have restrictive funding arrangements that tie them to a particular lab or Principal Investigator's research focus, she says.US visa restrictions can often mean missing family events back home. Majumdar, for example, who gained a biochemistry and molecular biology PhD from the University of Georgia in Athena in 2014, could not return to India to attend her parents' funerals. “It was probably the biggest sacrifice I've had to make in my life,” she says. In the final episode of a six-part podcast series covering books about the scientific workplace, Majumdar, who is now assistant Dean for professional development at Princeton University in New Jersey, tells Holly Newson that having a “growth mindset” can help international scientists to thrive abroad. This means not focusing on problems, but on possibilities and solutions, she says, supported by advisors, mentors, and sponsors. The US, she says, has a reputation as a melting pot of different cultures, a place to meet colleagues with a shared passion for science and solving problems. But in the last decade the climate for researchers who relocate there from abroad has become more difficult, she adds. Hosted on Acast. See acast.com/privacy for more information.

The Rao Lab at Seattle Children's Research Institute developed a three-dimensional (3D) tissue-engineered model of osteosarcoma to investigate the effects of the extracellular matrix on malignant cell function. The study demonstrated that culturing osteosarcoma (OS) cells within a 3D collagen matrix induced unique cellular responses, altered morphology, enhanced tumorigenic behavior, and reduced chemosensitivity compared to cells cultured in 2D collagen or on standard tissue culture plastic. They identified overexpression of drug efflux pumps as a key mechanism of chemoresistance and further showed that a tyrosine kinase inhibitor could suppress drug efflux activity, thereby enhancing the efficacy of standard chemotherapeutic agents.While this earlier study examined the effects of a single collagen concentration on osteosarcoma phenotype, clinical solid tumors are characterized by altered extracellular microarchitecture, including increased matrix density and stiffness. These changes restrict drug transport and limit chemotherapy-induced cell death.Dr. Rao will present findings from engineered tumor models incorporating varying matrix densities and demonstrate how matrix density influences osteosarcoma function. This work was funded by the 2025 Outsmarting Osteosarcoma Young Investigator Hope Award.Dr. Rao is a Pediatric Hematologist Oncologist at the Seattle Children's Hospital and a Principal Investigator in the Ben Towne Center for Childhood Cancer and Blood Disorders Research at the Seattle Children's Research Institute. His lab harnesses biomaterials and tissue engineering technologies to design 3D models of osteosarcoma to understand how cell-matrix interactions lead to chemoresistance.

April 2, 2026 ~ Dr. Pooja Green, Principal Investigator SOS MATERNITY Network, Maternal Fetal Medicine Specialist, Trinity Health Ypsilanti joins Dr. Sonia Hassan in for Paul W. Smith. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Phil Wolfson offers his seasoned perspective on psychedelics, ketamine assisted therapy, and more in this expansive talk with Raghu Markus and Gagan Levy.Check out these FREE personal & clinical guidelines for use from the Ketamine Research FoundationThis week on Mindrolling, Raghu, Phil, and Gagan discuss:How psychedelics shaped Phil's worldview in the 1960s and inspired his commitment to social justiceUsing psychedelics as tools for personal growth, healing, and transformationThe importance of set and setting when taking psychedelics recreationally, therapeutically, or ceremoniously Going beyond the ups and downs of psychedelics and finding steady peace through practiceThe persistent anti-depressant effects of Ketamine and its therapeutic promisePhil's ongoing studies with the Ketamine Research Foundation for phantom limb pain, end-of-life care, and menstrual cycle disordersMind Manifesting: What exactly happens to the brain on psychedelics?Phil's ‘bottom line': positive intentions and practical guidelines for Ketamine useAbout Dr. Phil Wolfson:Phil Wolfson MD was Principal Investigator for the MAPS sponsored Phase 2, FDA approved 18-person study of MDMA Assisted Psychotherapy for individuals with significant anxiety due to life threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine Assisted Psychotherapy. Phil's book, The Ketamine Papers, has been published by MAPS and is the seminal work in the burgeoning ketamine arena. Phil is a sixties activist, psychiatrist/psychotherapist, writer, practicing Buddhist and psychonaut who has lived in the Bay Area for 38 years. He is the author of Noe: A Father/Son Song of Love, Life, Illness and Death (2011, North Atlantic Books). He has been awarded five patents for unique herbal medicines. He is a journalist and author of numerous articles on politics, transformation, psychedelics, consciousness and spirit, and was a founding member of the Heffter Research Institute. Phil has taught in the graduate psychology programs at JFK University, CIIS and the UCSF School of Medicine Department of Psychiatry. Phil is the founder and CEO of the Ketamine Research Foundation and is committed to making the organization a vibrant contributor to the betterment of human beings through psychedelic psychotherapy."The work needs to be thought of not as a single episode, but as a therapy. Psychedelic psychotherapy is much quicker than conventional psychotherapy for many reasons, but it needs to have a follow-up, continuation, integration, and work with someone to be effective. That's not to say ketamine on its own doesn't have value, it does." – Dr. Phil WolfsonAbout Gagan Levy:Gagan Levy is the Founder/CEO of Guru, an award-winning creative agency dedicated to serving purpose-driven movements, brands, and organizations. They work with impactful brands like Patagonia, Traditional Medicinals, Nalgene, Non-GMO, The Organic Alliance, Bring Change to Mind and many natural products brands, including EO / Everyone Products, OM Mushroom Superfoods, and REBBL. Gagan also serves as Chief Evangelist at MAHA Global, a platform focused on helping businesses adapt to stakeholder needs using data-driven reputation intelligence. As former Co-chair of Social Venture Circle, one of the country's most prestigious impact investor and social business communities, Gagan leads the way to a next economy that is regenerative, just, and prosperous for all. Gagan Levy is also a current board member to his prolific teacher Ram Dass' Love Serve Remember Foundation, he has been instrumental in strategizing how to connect the greatest wisdom keepers of our time to a new generation. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week Clint speaks with Dr. Shawn McNeil & Dr. Donard.  In this conversation they explore the latest research and clinical practices in psychiatry, focusing on schizophrenia, genetic testing, early detection, and the impact of AI on mental health.    Dr. Shawn McNeil hosts an Apple podcast, "Addiction Medicine: Beyond the Abstract" Addiction Medicine: Beyond the Abstract - Podcast - Apple Podcasts. A quarterly, interactive addiction journal club was discussed, paired with presentation Dr. McNeil discusses on his podcast. https://podcasts.apple.com/us/podcast/addiction-medicine-beyond-the-abstract/id1806152019   Biography Dr. Shawn McNeil is a physician and researcher at LSU Health Shreveport. He is a Clinical Assistant Professor in the Department of Psychiatry and Behavioral Medicine and serves as Program Director of the Psychiatry Residency Program and Director of Neuroinformatics Research. He is a diplomate of the American Board of Psychiatry & Neurology and is board-certified in General Psychiatry and Child & Adolescent Psychiatry. He completed his Psychiatry residency at LSU Health Shreveport and is a recipient of the Resident Recognition Award from the American Psychiatric Association (APA). He also completed his fellowship in Child & Adolescent Psychiatry at LSU Health, serving as chief resident of the program.   Clinically, Dr. McNeil practices at Louisiana Behavioral Health where he serves as Chief Medical Officer. He also supervises residents at the Ochsner LSU Health Ambulatory Care Center. His primary research is clinical in nature. He is Principal Investigator on a clinical trial (Apathy in Schizophrenia, Intra-Cellular Therapies, Inc.) at the LSU Health Psychiatry Research Clinic which is investigating the use of Lumateperone on motivation in patients with psychotic disorders. He previously worked on the Blüm Autism Study (sponsored by Curemark) and the Tapestry Autism Study (sponsored by Axial Therapeutics). He is also the Director of Clinical Research for the Louisiana Addiction Research Center.   Dr. McNeil serves as President of the Louisiana Psychiatric Medical Association (LPMA). He is on the editorial board of the Journal of Addiction Medicine (JAM) and is host of their podcast "Addiction Medicine: Beyond the Abstract". He is a 2018 recipient of the ASAM's Ruth Fox Memorial Endowment Scholarship. He has also served on the editorial board of the APA's American Journal of Psychiatry Resident's Journal and he has been recognized as a Fellow of the APA.   Dr. McNeil was previously a staff physician at the Overton Brooks VA Medical Center and treated veterans in the Post-Traumatic Stress Disorder Clinic. He continues to proudly serve as a Deputy Coroner of Caddo Parish, Louisiana.     Donard Dwyer, PhD Professor of Psychiatry and Behavioral Medicine   Biography Donard Dwyer received his BS degree in Psychology from Tulane University, a Master's degree in education (MEd) from the University of Rochester and his PhD from the University of Alabama at Birmingham (UAB). In addition, to holding positions as a Research Scientist at the Max-Planck Society laboratories in Würzburg, Germany and Director of Immunology at a Cambridge biotechnology company, Dr. Dwyer has spent 32 years in academic research at UAB and LSU Health Shreveport. He is currently professor of Psychiatry and Pharmacology, Toxicology and Neuroscience at LSU Health Shreveport. In addition, he is Vice-Chair for Research in the Department of Psychiatry.   His research interests range broadly from the evolution of protein ligand-receptor interactions, the electronic properties of amino acids and regulation of glucose transport in neurons to behavioral genetics of motivation and movement in C. elegans and the genetic basis for schizophrenia and neuropsychiatric disorders. He is currently focused on the role of insulin signaling pathways in regulation of motivation in “suicidal” worms and characterization of the genetic architecture of schizophrenia with mathematical approaches. Finally, his laboratory is searching for drugs that produce neuroenhancement in cultured neurons as potential treatments for an array of neuropsychiatric conditions.     Medical Trial: https://www.lsuhs.edu/departments/school-of-medicine/psychiatry-and-behavioral-medicine/research   Chapters 00:00 Introduction to the Podcast and Guests 02:27 Overview of Schizophrenia and Motivation Challenges 04:23 The New Drug Adalumid Teparone and Its Potential 07:50 Understanding Schizophrenia: Causes and Risk Factors 12:04 Genetics of Schizophrenia: Myths and Realities 16:20 Enrolling Patients in Clinical Trials 20:49 Genetic Testing and Personalized Medicine in Psychiatry 25:54 Early Signs of Psychosis in Children 30:50 Supporting Families and Community Resources 40:04 The Role of AI in Future Psychiatry 52:17 AI and the Risks of Artificial Relationships 56:35 Conclusion: Hope and the Future of Mental Health Care

Jonathan Martinis, Director of Knowledge Translation for the DEP RRTC, and Barry Whaley, Director of the Southeast ADA Center, join the DEP RRTC's Let's Get to Work podcast to discuss how knowledge translation can connect research, policy, and real-world impact. Peter Blanck, University Professor and Chairman of the Burton Blatt Institute at Syracuse University and Principal Investigator of the DEP RRTC, hosts a conversation focused on the importance of “conveying information to people that is useful, robust, accessible, and in plain language to both improve disability employment policy and disability employment.” To that end, Jonathan explains that knowledge translation is more than just providing information; it's about connecting information to action. “Knowledge translation is a bridge,” he says. “It is a bridge between what we know or what we're going to find out and what we're doing.” Barry emphasizes that knowledge translation must engage stakeholders and be responsive to their needs, saying, “unless there is communication with the people receiving that information and that it is useful to them, then we've not succeeded in our mission.” Together, Jonathan and Barry discuss how the DEP RRTC and Southeast ADA Center are using multiple tools to translate complex research and resources into practical guidance, with a clear focus: “Knowledge translation is what makes good information into good policy and practice.”

SMALL-CAP MARKET INTELLIGENCE — MARCH 26, 2026Defense, biotech, resources and critical minerals dominate today's small-cap tape with a wave of catalysts across nine companies.Defense & Technology Lead the ChargeDraganfly Inc. (DPRO) anchors today's session with a sweeping corporate update confirming $145 million in cash — nearly matching its current market cap — while flagging growing U.S. defense contracts, including a supply deal with Air Force Special Operations Command and a perfect score in the Secretary of War's Drone Dominance Program. Meanwhile, Nextech3D.ai (NTAR) announced the addition of Apple Pay and Google Pay to its blockchain ticketing stack, completing a mainstream-ready payment infrastructure that lets attendees buy verifiable on-chain tickets with no crypto knowledge required. The platform is now positioned for enterprise and government deployment across thousands of events.Biotech MilestoneQuantum BioPharma (QNTM) named Harvard-affiliated neurologist Dr. Salvatore Napoli as Principal Investigator for its planned Phase 2 trial of Lucid-MS, a first-in-class compound targeting demyelination in Multiple Sclerosis. Napoli brings over 20 years of clinical and research experience from the Brigham and Women's Hospital and Harvard Medical School. An FDA Investigational New Drug application is expected within weeks — a critical regulatory milestone before clinical evaluation can begin.Oil & Gas: Namibia in PlayReconAfrica (RECO) has commenced production testing at its Kavango West 1X discovery in Namibia, with updated petrophysical analysis boosting net hydrocarbon pay to 75 metres — up from 64 metres previously. Six zones spanning 345 metres of prospective interval will be tested using Halliburton and Schlumberger services, setting up a near-term production catalyst.Critical Minerals in FocusNouveau Monde Graphite (NOU) executed a binding long-form offtake framework with the Government of Canada for 30,000 tonnes per year of graphite concentrate from its Matawinie Mine in Québec — on a take-or-pay basis over a seven-year term. The deal complements US$335M in committed senior secured project debt from Export Development Canada and the Canada Infrastructure Bank, clearing a path to a positive Final Investment Decision. SAGA Metals (SAGA) acquired a 120-claim titanium project directly from Rio Tinto in Quebec's Havre-Saint-Pierre Anorthosite Complex — the same district as Rio Tinto's world-class Lac Tio operation — with grab samples returning 32.4% TiO₂, 65.1% Fe₂O₃ and 2,260 ppm vanadium. Antimony Resources (ATMY) continues to impress at its Bald Hill project in New Brunswick, where the newly discovered Marcus (West) Zone has expanded to 80 metres of exposed massive stibnite mineralization, resembling the main zone in concentration, while 6,500 of a planned 10,000-metre drill program is complete.Gold ShinesAton Resources (AAN) reported standout polymetallic results from Abu Marawat in Egypt's Eastern Desert, including 21.85 g/t Au, 178 g/t Ag, 0.55% Cu and 5.21% Zn over 20 metres — the kind of high-grade, multi-commodity intercept that underscores the deposit's strategic value. Omai Gold Mines (OMG) further cemented its Tier 1 credentials in Guyana with drill results of 7.74 g/t Au over 13.5m and 10.02 g/t Au over 5.4m at the Wenot deposit. With five rigs turning, an updated Mineral Resource Estimate expected within weeks, and a new geophysical drill target — "The Handle" — now underway, Omai continues to build scale rapidly.AGORACOM Small Cap Breaking News | agoracom.com

How can teacher educators build spaces “outside the system” for critical, community-engaged, and personal work? As members of our Writing & Literacies and broader AERA communities travel to LA for this year's AERA annual conference, we invite you to download this Soundcloud exclusive episode for your travel day. Joining us on this episode of Inquiring Minds are two scholars and teacher educators who live and work in the greater Los Angeles area. From California State Dominguez Hills, professors Stephanie Cariaga and Edward Curammeng discuss teacher education at the intersections of critical literacies, ethnic studies, and trauma-informed perspectives on healing. Stephanie Cariaga has served the wider Los Angeles community for about two decades as an English teacher, founding member of the People's Education Movement, and is now an associate professor in teacher education at California State University Dominguez Hills. She is the founder of CrEW — Critical Embodied Wellness for Educators — a space of refuge, restoration, and resistance that supports radical educators to teach and lead from the wisdom of their whole selves. Her teaching and research seek to reintegrate the mind, body, and spirit into classrooms and beyond to cultivate spaces of truth-feeling and healing with marginalized students and educators. She is inspired by many teachers, including Black and Brown feminist world-makers, her ancestors, CrEW co-conspirators, and most of all: her children Laila and Lino. Edward R. Curammeng (Ph.D., Education, UCLA) is an Associate Professor in the College of Education and Graduate Program Director for the MA in Education at California State University, Dominguez Hills. His teaching and research interests include Ethnic Studies Education and critical race theory in education to examine the experiences of students and teachers of color. His scholarship has been published in Review of Educational Research, Teacher Education Quarterly and Journal of Asian American Studies. Upon transferring from Ohlone College, he earned his BA and MA in Asian American Studies from San Francisco State University where he taught middle and high school Filipino American and Ethnic Studies with Pin@y Educational Partnerships. Curammeng is the Project Director and Principal Investigator for the U.S. Department of Education funded Multilingual/Minoritized Educators Networked-Learning and Development (MEND) project.

Send us Fan MailDr. Jochen Profit, Chair and Principal Investigator at CPQCC and Wendy J. Tomlin-Hess Endowed Professor of Pediatrics at Stanford Medicine, joins the podcast to discuss what truly separates high performing NICUs from the rest. He makes the case for process metrics over mortality as quality markers, highlighting normothermia on admission, breast milk feeding at discharge, and infection rates as deceptively simple yet deeply revealing indicators of unit culture. The conversation also explores how toxic work environments and provider burnout silently undermine quality improvement efforts.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below.Enjoy!

As a cultural powerhouse, the Caribbean region has the potential to become a digital leader in leveraging AI and VR technologies to preserve the region's unique identity, modernise its education systems, and ensure that digital inclusion reaches every citizen. Amanda Zilla, the Principal Investigator of the dream LAB, within the Artificial Intelligence Innovation Centre (AIIC), joins us to discuss, among other things,   *  the ways in which AI and VR can be leveraged in areas such as the arts, culture, and education;   *  how VR and AI can help Caribbean people to better engage with their own history;   *  how the dream LAB is navigating thorny issues such as copyright and cultural appropriation; and   *  how AI-enhanced VR experiences help countries further develop their tourism product beyond sea and sand.    The episode, show notes and links to some of the things mentioned during the episode can be found on the ICT Pulse Podcast Page (www.ict-pulse.com/category/podcast/)       Enjoyed the episode?  Do rate the show and leave us a review!       Also, connect with us on: Facebook – https://www.facebook.com/ICTPulse/   Instagram –  https://www.instagram.com/ictpulse/   Twitter –  https://twitter.com/ICTPulse   LinkedIn –  https://www.linkedin.com/company/3745954/admin/   Join our mailing list: http://eepurl.com/qnUtj    Music credit: The Last Word (Oui Ma Chérie), by Andy Narrell Podcast editing support:  Mayra Bonilla Lopez   ---------------

In this special re-run episode of The Crop Science Podcast Show, we bring back our conversation with Dr. Phuong Dao from Colorado State University, who shares cutting-edge insights into how remote sensing, AI, and geospatial science are transforming precision agriculture. Learn how high-resolution hyperspectral imaging and machine learning are helping detect crop issues, optimize yields, and prepare the next generation of agricultural data scientists. Listen now on all major platforms!"Remote sensing provides a non-destructive and rapid method to detect and monitor disturbances in crops."Meet the guest: Dr. Phuong Dao is an Assistant Professor at The University of Texas at Austin and Principal Investigator of the Remote Sensing and Environmental Intelligence Lab. Research focuses on integrating remote sensing, geospatial science, plant ecology, and machine learning to understand crop disturbances and plant responses. Work connects plant physiology, environmental stress, and precision agriculture technologies for improved crop monitoring. Liked this one? Don't stop now — Here's what we think you'll love!What you will learn:(00:00) Highlight(00:59) Introduction(04:19) Remote sensing use(06:04) Hyperspectral imaging(13:04) Future of ag tech(15:29) AI in crop science(18:01) Workforce development(22:52) Final three questionsThe Crop Science Podcast Show is trusted and supported by innovative companies like:- KWS

A nontechnical talk by Dr. Bruce Macintosh (University of California Observatories)Mar. 11, 2026In the past three decades, more than 6000 planets have been discovered orbiting other stars.  Advances in technology have allowed a handful of giant planets around other stars to be imaged directly. Dr. Macintosh tells us about the first-ever images of other solar systems — and the technology that has allowed us to discover them, such as the Gemini Planet Imager — as well as the future planet-hunting space telescopes. The ultimate goal is detection of a second ‘pale blue dot' — an Earth twin where we could even see the biosignatures of extrasolar life.  (He also talks a bit about the wind damage to the Lick Observatory and what is being done to repair the historic dome.)Bruce Macintosh is the Director of the University of California Observatories in California and Hawaii. He co-led the team that imaged the first extrasolar planets, and was the Principal Investigator of the Gemini Planet Imager, an advanced planet-finder for the Gemini South telescope.

More information, bios, and transcript available at: https://bbi-dep-rrtc.org/resources/podcast-series/lgtw-beth-23/ Beth Sirull, President and CEO of the National Organization on Disability (NOD), joins the DEP RRTC's Let's Get to Work podcast to discuss the future of disability employment policy and why employing people with disabilities “is good for business.” Beth explains that NOD has long focused on employment as a pathway to independence and economic opportunity for people with disabilities because, “if you don't have a way to support yourself, there's just no way that you can manifest the American Dream.” Peter Blanck, University Professor and Chairman of the Burton Blatt Institute at Syracuse University and Principal Investigator of the DEP RRTC, joins Beth in a conversation about how NOD works with employers to unlock the vast, often overlooked talent pool of people with disabilities. Beth emphasizes that employing people with disabilities results in real benefits to businesses, including lower turnover and stronger employee engagement. “[I]f you hire someone with a disability and you provide them with the accommodation that they need,” she says, “they will not leave. You will have a very loyal, longstanding, productive employee.” Ultimately, Beth emphasizes, disability employment policy is about “putting everyone in a situation where they can be maximally effective in their job, which obviously is what companies want.”

A key question about the early history of the Solar System is whether the giant planets formed roughly at the distances from the Sun they presently occupy, or, as some theories predict, much closer to the Sun. The discovery of other solar systems with radically different configurations of planets has made this question more pressing, since it appears that the configuration of the Solar System might be atypical. In the podcast, Hal Levison explains why the Trojan asteroids of Jupiter offer us the best opportunity to discriminate between the various models of Solar System evolution. And that is why a spacecraft called Lucy is now well on its way to a rendezvous with these asteroids. Hal Levison is the Principal Investigator of the Lucy mission. He studies the dynamics of astronomical objects and, in particular, the formation and long-term behavior of solar system bodies. He is one of the original proponents of the Nice model (named after the city where it was conceived), a scenario that proposes the migration of the giant planets from an initial compact configuration closer to the Sun to their present positions. He is Chief Scientist in the Department of Space Sciences at the Southwest Research Institute in Boulder, Colorado.

Today's guest is Jason Luoma, PhD. Jason is a clinical psychologist, researcher, entrepreneur, and psychotherapy trainer based in Portland, Oregon. For over two decades, Jason's research has focused on shame, stigma, and the interpersonal functions of emotion, with more recent work centered on psychedelic science. He served as Principal Investigator on one of the first MDMA-assisted psychotherapy trials in the Pacific Northwest and has contributed to multiple NIH-funded clinical trials in roles including co-investigator, consultant, therapist, and trainer.Jason is co-author of the bestselling ACT text Learning Acceptance and Commitment Therapy and Values in Therapy, and is currently writing a book on psychedelic-assisted therapy for Guilford Press. A longtime leader in the ACT community, he is a peer-reviewed ACT trainer, former president of the Association for Contextual Behavioral Science, and co-founder of several innovative organizations, including the Portland Psychotherapy Clinic, Research, & Training Center and the Portland Institute for Psychedelic Science.He also hosts The Research Matters Podcast, where he interviews leading researchers about what makes their work impactful and effective.Some of the topics we explore in this episode include:-His early development in Steve Hayes' lab-The evolution of ACT and contextual behavioral science-The need for more experiential learning for clinicians -psychedelics and their application for healing-Hopes for the future of psychedelic assisted therapy —————————————————————————Jason's Website: https://jasonluoma.com/—————————————————————————Thank you all for checking out the episode! Here are some ways to help support Mentally Flexible:You can help cover some of the costs of running the podcast by donating a cup of coffee! www.buymeacoffee.com/mentallyflexiblePlease subscribe and leave a review on Apple Podcasts. It only takes 30 seconds and plays an important role in being able to get new guests.https://podcasts.apple.com/us/podcast/mentally-flexible/id1539933988Follow the show on Instagram: https://www.instagram.com/mentallyflexible/Check out my song “Glimpse at Truth” that you hear in the intro/outro of every episode: https://tomparkes.bandcamp.com/track/glimpse-at-truthCheck out my new album, Holding Space! https://open.spotify.com/album/0iOcjZQhmAhYtjjq3CTpwQ?si=nemiLnELTsGGExjfy8B6iw

Welcome to Transmission Interrupted! In this episode, host Jill Morgan sits down with the principal investigators of NETEC—Dr. Aneesh Mehta, Dr. Vikramjit Mukherjee, and Dr. John Lowe—to reflect on a decade of advancing special pathogen preparedness across the U.S. healthcare system. Together, they revisit the origins of NETEC, tracing back to the transformative events of the 2014 Ebola outbreak, and share their unique journeys as infectious disease experts, critical care clinicians, and scientists on the front lines. The conversation dives into the challenges and lessons learned while building a national network equipped for high-consequence infectious diseases, the evolution from isolated specialty units to a system-wide approach, and the critical importance of healthcare worker safety. You'll hear insights on what it takes to maintain readiness in a landscape of ever-changing threats, the value of interdisciplinary collaboration, and a call to expand this “tight-knit club” of preparedness champions. Whether you're a healthcare professional, public health advocate, or just curious about how the U.S. prepares for medical crises, this episode delivers an inspiring look at the past, present, and future of special pathogen response—and why it matters to us all. Guests John-Martin Lowe, PhD John-Martin Lowe, PhD, is the director of the Global Center for Health Security, assistant vice chancellor for health security training and education, and professor of Environmental, Agricultural and Occupational Health at the University of Nebraska Medical Center. At the University of Nebraska Medical Center, he leads research and training initiatives to advance environmental risk assessment and infection control for high consequence pathogens. As a virologist and environmental exposure scientist, Dr. Lowe has worked extensively throughout the U.S., Africa, Asia and Europe as an educator, researcher, and in health emergency risk management related to infectious disease, infection control and emergency response. As a professor of environmental and occupational health, his expertise focuses on infectious disease risk assessment and management of risk for clinical, community and industrial environments. Dr. Lowe also has extensive experience in emerging pathogens and health security. He is co-PI for the U.S. National Emerging Special Pathogens Training and Education Center, established an international network for emerging infectious diseases, and served lead investigator for a multi-country bio-surveillance network in Africa. He has experience in a broad range of health security topics from surveillance, public health response and clinical response to health emergencies. Dr. Lowe led successful COVID-19 efforts in 2020 at the National Quarantine Unit and Nebraska Biocontainment Unit to provide monitoring and care for repatriated U.S. citizens exposed to and infected with SARS Coronavirus 2. He also led early and continued efforts to characterize the transmission dynamics of SARS Coronavirus 2 which were presented to in a joint meeting hosted by the Academy of Medicine and American Public Health Association on April 15, 2020. Dr. Aneesh Mehta, MD, FIDSA, FAST Aneesh Mehta is a Professor of Medicine and of Surgery at Emory University School of Medicine, and also serves as the Chief of Infectious Diseases Services and Assistant Director of Transplant Infectious Diseases at Emory University Hospital. He is a board-certified infectious diseases physician, who received an MD from the University of Oklahoma and completed Internal Medicine and Infectious Diseases training at Emory University. Aneesh has been one of the core physicians of the Emory Serious Communicable Diseases Unit (SCDU) since 2009. He was admitted physician for Emory's first patient with Ebola Virus Disease and was highly involved in care of the four patients with EVD, one patient with Lassa Fever, and several PUIs cared for by the Emory SCDU. During the Ebola activation, Aneesh was involved in all aspects of unit management, patient care, laboratory handling, and research. Aneesh is a co-Principal Investigator at NETEC. He also has been involved in development of the Special Pathogens Research Network Biorepository and evaluation of Medical Countermeasures. Vikramjit Mukherjee, MD, FRCP (Edin) Vikramjit Mukherjee is an intensive care physician who serves as the Chief of Critical Care at NYC Health+Hospitals/Bellevue. He also is the Chief of Bellevue's Special Pathogens Program. Dr. Mukherjee is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care and Sleep Medicine at the NYU Grossman School of Medicine. Dr. Mukherjee serves as co-Principal Investigator for NETEC, as a steering committee member for the National Special Pathogens System of Care, and as an executive member of the Task Force for Mass Critical Care. His research interests include special pathogen preparedness and mass critical care. Vikramjit Mukherjee completed his medical training at Armed Forces Medical College, India, before arriving in the United States. Here, he completed his residency and chief residency at Georgetown University/Washington Hospital Center and fellowship and chief fellowship in Pulmonary and Critical Care Medicine at New York University Medical Center. Following completion of training in 2015, he joined faculty in the Division of Pulmonary, Critical Care and Sleep Medicine at New York University Grossman School of Medicine. Host Jill Morgan, RN Emory Healthcare, Atlanta, GA Jill Morgan is a registered nurse and a subject matter expert in personal protective equipment (PPE) for NETEC. For 35 years, Jill has been an emergency department and critical care nurse, and now splits her time between education for NETEC and clinical research, most of it centering around infection prevention and personal protective equipment. She is a member of the Association for Professionals in Infection Control and Epidemiology (APIC), ASTM International, and the Association for the Advancement of Medical Instrumentation (AAMI). Resources About NETECNETEC LeadershipTransmission Interrupted PodcastNational Special Pathogen System (NSPS)NETEC Resource Library About NETEC A Partnership for Preparedness The National Emerging Special Pathogens Training and Education Center's mission is to set the gold standard for special pathogen preparedness and response across health systems in the U.S. with the goals of driving best practices, closing knowledge gaps, and developing innovative resources. Our vision is a sustainable infrastructure and culture of readiness for managing suspected and confirmed special pathogen incidents across the United States public health and health care delivery systems. For more information visit NETEC on the web at www.netec.org. NETEC Consultation Services Assess and Advance Your Readiness for Special Pathogens with Free, Expert Consulting. NETEC offers free virtual and onsite readiness consulting to help health care facilities and EMS agencies prepare for special pathogen events. Our targeted support services are delivered by experts selected and assigned to each inquiry based on the unique needs of your organization. Have a question? Ask a NETEC expert. For more information visit: netec.org/consulting-services.

Guest: Dr. Ido Amit is a Principal Investigator and the Eden and Steven Romick Professorial Chair at the Weizmann Institute of Science. His lab is at the forefront of developing and applying cutting-edge single-cell genomics technologies alongside advanced computational approaches. By integrating these innovative tools in both animal models and human studies, his team uncovers the immune regulatory mechanisms and pathways that shape health and disease. Featured Products and Resources: Stay up-to-date with the latest in human immunology news. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Modified RNA Prevents Autoimmunity – Researchers show that modified RNA from our own cells naturally blocks TLR7 and TLR8, preventing harmful immune activation. Oncolytic Virus Boosts T Cells – In glioblastoma patients, a single virus treatment helped the immune system attack the tumor. Rewiring the Immune System During Food Scarcity – When food is scarce, stress hormones rebalance the immune system to fight infection while conserving glucose and preserving immune memory. Regulating Bystander T Cells – IL-4 can dial down how strongly memory CD8+ T cells respond to infection without direct antigen stimulation. Image courtesy of Dr. Ido Amit Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Guests:Dr Michel Dugon, Assistant Professor in Zoology and Principal Investigator of the Venom Systems Lab at the University of GalwayDr Jessamyn Fairfield, Lecturer in the School of Natural Sciences at the University of GalwayDr Laura Hayes, Research Fellow at the School of Cosmic Physics at DIAS

One of the most exciting missions to ever journey to the outer solar system has the be the Dragonfly multi-rotor helicopter that will head to Saturn's moon Titan in 2028. The car-sized probe will arrive at that strange, frozen world in 2034, descending into the soupy, smoggy atmosphere and then taking flight before it even touches the ground! We spoke with the mission's Principal Investigator, Dr. Elizabeth "Zibi" Turtle, about the mission's origins, current progress, and what to expect in the coming years. She also took us through a narrated tour of the surface of Titan, with its hydrocarbon sand dunes and methane seas. The Dragonfly mission will be an adventure of a lifetime! Headlines: NASA's Artemis II Moon Rocket Aces New Fueling Test Boeing Starliner is Rated a "Type A" Mishap and Faces More Launch Delays Perseverance Rover Gets Instant Mars GPS-like Functionality Main Topic: NASA's Dragonfly Mission to Titan Dr. Elizabeth Turtle explains Dragonfly's origins and mission concept Why Titan is unique and somewhat akin to the primordial Earth, perfect for exploring prebiotic chemistry Dragonfly's advanced science suite and autonomous flying capability Insights from the Cassini/Huygens missions and how they are shaping Dragonfly Navigation, flight strategy, and safety planning for Titan's harsh environment Power, heating, and longevity on Titan's freezing surface Titan's dune landscape, flying conditions, and analogs to Earth Big scientific questions: methane cycle, atmospheric mysteries, and potential surprises Mission timeline, lander design, and the innovative "fly-as-you-land" arrival approach Hosts: Rod Pyle and Tariq Malik Guest: Dr. Elizabeth Turtle Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit

One of the most exciting missions to ever journey to the outer solar system has the be the Dragonfly multi-rotor helicopter that will head to Saturn's moon Titan in 2028. The car-sized probe will arrive at that strange, frozen world in 2034, descending into the soupy, smoggy atmosphere and then taking flight before it even touches the ground! We spoke with the mission's Principal Investigator, Dr. Elizabeth "Zibi" Turtle, about the mission's origins, current progress, and what to expect in the coming years. She also took us through a narrated tour of the surface of Titan, with its hydrocarbon sand dunes and methane seas. The Dragonfly mission will be an adventure of a lifetime! Headlines: NASA's Artemis II Moon Rocket Aces New Fueling Test Boeing Starliner is Rated a "Type A" Mishap and Faces More Launch Delays Perseverance Rover Gets Instant Mars GPS-like Functionality Main Topic: NASA's Dragonfly Mission to Titan Dr. Elizabeth Turtle explains Dragonfly's origins and mission concept Why Titan is unique and somewhat akin to the primordial Earth, perfect for exploring prebiotic chemistry Dragonfly's advanced science suite and autonomous flying capability Insights from the Cassini/Huygens missions and how they are shaping Dragonfly Navigation, flight strategy, and safety planning for Titan's harsh environment Power, heating, and longevity on Titan's freezing surface Titan's dune landscape, flying conditions, and analogs to Earth Big scientific questions: methane cycle, atmospheric mysteries, and potential surprises Mission timeline, lander design, and the innovative "fly-as-you-land" arrival approach Hosts: Rod Pyle and Tariq Malik Guest: Dr. Elizabeth Turtle Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit

One of the most exciting missions to ever journey to the outer solar system has the be the Dragonfly multi-rotor helicopter that will head to Saturn's moon Titan in 2028. The car-sized probe will arrive at that strange, frozen world in 2034, descending into the soupy, smoggy atmosphere and then taking flight before it even touches the ground! We spoke with the mission's Principal Investigator, Dr. Elizabeth "Zibi" Turtle, about the mission's origins, current progress, and what to expect in the coming years. She also took us through a narrated tour of the surface of Titan, with its hydrocarbon sand dunes and methane seas. The Dragonfly mission will be an adventure of a lifetime! Headlines: NASA's Artemis II Moon Rocket Aces New Fueling Test Boeing Starliner is Rated a "Type A" Mishap and Faces More Launch Delays Perseverance Rover Gets Instant Mars GPS-like Functionality Main Topic: NASA's Dragonfly Mission to Titan Dr. Elizabeth Turtle explains Dragonfly's origins and mission concept Why Titan is unique and somewhat akin to the primordial Earth, perfect for exploring prebiotic chemistry Dragonfly's advanced science suite and autonomous flying capability Insights from the Cassini/Huygens missions and how they are shaping Dragonfly Navigation, flight strategy, and safety planning for Titan's harsh environment Power, heating, and longevity on Titan's freezing surface Titan's dune landscape, flying conditions, and analogs to Earth Big scientific questions: methane cycle, atmospheric mysteries, and potential surprises Mission timeline, lander design, and the innovative "fly-as-you-land" arrival approach Hosts: Rod Pyle and Tariq Malik Guest: Dr. Elizabeth Turtle Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit

One of the most exciting missions to ever journey to the outer solar system has the be the Dragonfly multi-rotor helicopter that will head to Saturn's moon Titan in 2028. The car-sized probe will arrive at that strange, frozen world in 2034, descending into the soupy, smoggy atmosphere and then taking flight before it even touches the ground! We spoke with the mission's Principal Investigator, Dr. Elizabeth "Zibi" Turtle, about the mission's origins, current progress, and what to expect in the coming years. She also took us through a narrated tour of the surface of Titan, with its hydrocarbon sand dunes and methane seas. The Dragonfly mission will be an adventure of a lifetime! Headlines: NASA's Artemis II Moon Rocket Aces New Fueling Test Boeing Starliner is Rated a "Type A" Mishap and Faces More Launch Delays Perseverance Rover Gets Instant Mars GPS-like Functionality Main Topic: NASA's Dragonfly Mission to Titan Dr. Elizabeth Turtle explains Dragonfly's origins and mission concept Why Titan is unique and somewhat akin to the primordial Earth, perfect for exploring prebiotic chemistry Dragonfly's advanced science suite and autonomous flying capability Insights from the Cassini/Huygens missions and how they are shaping Dragonfly Navigation, flight strategy, and safety planning for Titan's harsh environment Power, heating, and longevity on Titan's freezing surface Titan's dune landscape, flying conditions, and analogs to Earth Big scientific questions: methane cycle, atmospheric mysteries, and potential surprises Mission timeline, lander design, and the innovative "fly-as-you-land" arrival approach Hosts: Rod Pyle and Tariq Malik Guest: Dr. Elizabeth Turtle Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free audio and video feeds, a members-only Discord, and exclusive content. Join today: https://twit.tv/clubtwit

In Pathology of Plenty: Natural Resources in International Law (Bloomsbury 2025), Lys Kulamadayil offers a crucial examination of how international law shapes the exploitation of natural resources in post-colonial States. Kulamadayil reveals how international legal rules can be constitutive, punitive, remedial in creating the paradox of plenty in resource-rich States. The book revisits the making of foundational principles like sovereignty over natural resources and economic self-determination as applied during decolonisation; explores how humanitarian frameworks have justified extraction of public natural resources; and traces the proliferation of international treaties that protect foreign property rights. The book also zooms in on legal paradigms ranging from contract law to anti-corruption, human rights, and criminal law, arguing that these frameworks often work together to create the pathology of plenty. Through this interrogation, the book points to proposals to escape siloed ways of thinking about natural resources and embrace an intersectoral and anti-carceral thinking instead. Lys Kulamadayil is a Swiss National Science Foundation Ambizione Fellow at the Graduate Institute of International and Development Studies in Geneva and the Principal Investigator of the project Law by Colour Code: Locating Race and Racism in International Law. Raghavi Viswanath is a postdoctoral researcher and teaching fellow at SOAS, University of London. Her research, supported by the Leverhulme Trust, examines how pastoralists claim grazing rights under India's Forest Rights Act 2006 and how the everyday processes of staking such claims has been impacted by the authoritarian turn in India. LinkedIn. Email:rv13@soas.ac.uk Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In Pathology of Plenty: Natural Resources in International Law (Bloomsbury 2025), Lys Kulamadayil offers a crucial examination of how international law shapes the exploitation of natural resources in post-colonial States. Kulamadayil reveals how international legal rules can be constitutive, punitive, remedial in creating the paradox of plenty in resource-rich States. The book revisits the making of foundational principles like sovereignty over natural resources and economic self-determination as applied during decolonisation; explores how humanitarian frameworks have justified extraction of public natural resources; and traces the proliferation of international treaties that protect foreign property rights. The book also zooms in on legal paradigms ranging from contract law to anti-corruption, human rights, and criminal law, arguing that these frameworks often work together to create the pathology of plenty. Through this interrogation, the book points to proposals to escape siloed ways of thinking about natural resources and embrace an intersectoral and anti-carceral thinking instead. Lys Kulamadayil is a Swiss National Science Foundation Ambizione Fellow at the Graduate Institute of International and Development Studies in Geneva and the Principal Investigator of the project Law by Colour Code: Locating Race and Racism in International Law. Raghavi Viswanath is a postdoctoral researcher and teaching fellow at SOAS, University of London. Her research, supported by the Leverhulme Trust, examines how pastoralists claim grazing rights under India's Forest Rights Act 2006 and how the everyday processes of staking such claims has been impacted by the authoritarian turn in India. LinkedIn. Email:rv13@soas.ac.uk Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/world-affairs

In Pathology of Plenty: Natural Resources in International Law (Bloomsbury 2025), Lys Kulamadayil offers a crucial examination of how international law shapes the exploitation of natural resources in post-colonial States. Kulamadayil reveals how international legal rules can be constitutive, punitive, remedial in creating the paradox of plenty in resource-rich States. The book revisits the making of foundational principles like sovereignty over natural resources and economic self-determination as applied during decolonisation; explores how humanitarian frameworks have justified extraction of public natural resources; and traces the proliferation of international treaties that protect foreign property rights. The book also zooms in on legal paradigms ranging from contract law to anti-corruption, human rights, and criminal law, arguing that these frameworks often work together to create the pathology of plenty. Through this interrogation, the book points to proposals to escape siloed ways of thinking about natural resources and embrace an intersectoral and anti-carceral thinking instead. Lys Kulamadayil is a Swiss National Science Foundation Ambizione Fellow at the Graduate Institute of International and Development Studies in Geneva and the Principal Investigator of the project Law by Colour Code: Locating Race and Racism in International Law. Raghavi Viswanath is a postdoctoral researcher and teaching fellow at SOAS, University of London. Her research, supported by the Leverhulme Trust, examines how pastoralists claim grazing rights under India's Forest Rights Act 2006 and how the everyday processes of staking such claims has been impacted by the authoritarian turn in India. LinkedIn. Email:rv13@soas.ac.uk Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/environmental-studies

Kristof interviews Dr. Sarah HainesThe Indoor Microbiome is the complex, invisible world of microorganisms living within our daily surroundings, serving as the primary ecological interface through which buildings influence human biology. In this light, we are beginning to view indoor environments not merely as passive shelters, but as powerful positive health interventions that can actively shape our immune development and long-term wellbeing.Today, we are joined by Dr. Sarah Haines, Assistant Professor at the University of Toronto and Principal Investigator of the IMEE Lab, to explore the foundational framework behind this shift. We will discuss the emerging perspective of "biologically informed architectural design" and the fact that architects and interior designers don't just curate materials, they curate our basic microbial exposures and therefore our health and wellbeing. Sarah HainesProfessor Sarah Haines' interdisciplinary research integrates building science, engineering, and microbiology to analyze the impact the built environment has on human health. She uses cutting-edge microbiology techniques such as next-generation sequencing, metatranscriptomics, and bioinformatics to understand the impact of moisture on indoor environmental quality. Linking to climate change, her research explores the impact of weatherization and extreme weather events on indoor air quality, particularly in low income communities who may be at a higher risk for asthma. Her work aids in understanding indoor exposures from microorganisms and chemicals providing for a cleaner and sustainable indoor environment.TeamHosted by Kristof IrwinEdited by Nico MignardiProduced by M. Walker

While the Roman Empire conquered much of western Europe and established a powerful presence in Britain, Ireland remained beyond its grasp. But why? In this episode, I am joined by Dr Jacqueline Cahill Wilson to explore how Ireland interacted with the Roman world. It is a complex and intriguing story. Jacqueline reveals the considerable archaeological evidence that suggests Roman communities did exist in Ireland. If there was no invasion, however, this raises an obvious question: who were these people, why did they come to Ireland, and what were they doing there? Sound by Kate Dunlea. My guest on this episode is Dr Jacqueline Cahill Wilson. Originally from County Longford, she is a Research Fellow at the Royal Agricultural University in Cirencester. She holds an MA from the University of Reading and a PhD from the University of Bristol. From 2011 to 2015, she served first as Principal Investigator and later as Project Director of a major research project with the Discovery Programme in Dublin titled Late Iron Age and Roman Ireland. Her research focuses on social structures and identity in the past, and on how communities defined themselves and others through material evidence in the archaeological record. A key part of her work has involved the use of isotope geochemistry on human burials in Ireland, allowing researchers to identify where individuals originated from and challenging long held assumptions about identity and mobility in the past. Her work has consistently explored the interconnectedness of Ireland in its Iron Age with Britain and Europe under Roman control, periods that are often studied separately despite unfolding at the same time. She is currently working on a book titled Within or Without: Ireland in the Roman World, which brings together her doctoral research, the Discovery Programme project, and her subsequent research into a new historical study for a general readership. Hosted on Acast. See acast.com/privacy for more information.

The sense of hearing is a finely tuned collaboration between physics and biology, transforming invisible sound waves into meaning, memory, and emotion. From the delicate mechanics of the middle ear to the neural pathways that help us localize danger, recognize voices, and enjoy music, hearing quietly shapes how we connect with the world. Yet it's also one of our most vulnerable senses—affected by aging, noise exposure, infection, and even cardiovascular health. How benign are ear pain and ringing? Is there a limit to how loud we should listen to music? And what can we do to protect this sense before silence becomes noticeable?In this episode, we are joined by Dr. Stacey Lim, AuD, PhD, CCC-A, an American Speech-Language-Hearing Association (ASHA)-certified audiologist and Professor of Audiology.Dr. Lim received her BA in Communication Sciences and Disorders and German Language and Literature from Wooster College, her AuD (Doctor of Audiology) from the Northeast Ohio Au.D. Consortium at the University of Akron, and her PhD in Audiology from Kent State University. Currently, Dr. Lim is a Professor of Audiology at Central Michigan University, holds a Certificate of Clinical Competence in Audiology (CCC-A) from ASHA, and is a researcher focused on cochlear implants and aural rehabilitation, informed by her personal experience of bilateral, profound sensorineural hearing loss since birth. Previously, Dr. Lim was a Fulbright Scholar at the Ludwig Maximilian University of Munich, studying hearing loss in Germany, a co-Principal Investigator in March of Dimes research on cognitive and linguistic skills related to hearing loss, and the Chapter President at the Alexander Graham Bell Association for the Deaf and Hard of Hearing.Dr. Lim is also a co-curator of (dis)ABLED BEAUTY, a museum exhibition featuring creatively designed adaptive devices, assistive devices, and apparel for people with disabilities.Follow Friends of Franz Podcast: Website, Instagram, FacebookFollow Christian Franz (Host): Instagram, YouTube

Milk has long been sold as the key to strong bones, but research challenges that claim: many people don't tolerate dairy, calcium needs are lower than advertised, and higher milk intake doesn't necessarily prevent fractures. Politics and industry marketing helped set “three glasses a day,” even though healthy bones depend more on overall diet and lifestyle—things like vitamin D, movement, and avoiding soda, excess sugar, and stress that drive calcium loss. Dairy may be helpful for some diets, but it can also trigger bloating, acne, congestion, or digestive issues. The good news is that strong bones and good nutrition are still very doable without cow's milk—think leafy greens, sardines, almonds, chia, and sunshine for vitamin D. In this episode, I discuss, along with Dr. David Ludwig and Dr. Elizabeth Boham why bone health depends more on diet, lifestyle, and nutrient balance than on dairy. David S. Ludwig, MD, PhD, is an endocrinologist and researcher at Boston Children's Hospital, Professor of Pediatrics at Harvard Medical School, and Professor of Nutrition at the Harvard T.H. Chan School of Public Health. He co-directs the New Balance Foundation Obesity Prevention Center and founded the Optimal Weight for Life (OWL) program, one of the nation's largest clinics for children with obesity. For over 25 years, Dr. Ludwig has studied how diet composition affects metabolism, body weight, and chronic disease risk, focusing on low glycemic index, low-carbohydrate, and ketogenic diets. Called an “obesity warrior” by Time Magazine, he has championed policy changes to improve the food environment. A Principal Investigator on numerous NIH and philanthropic grants, Dr. Ludwig has published over 200 scientific articles and three books for the public, including the #1 New York Times bestseller Always, Hungry? Dr. Elizabeth Boham is Board Certified in Family Medicine from Albany Medical School, and she is an Institute for Functional Medicine Certified Practitioner and the Medical Director of The UltraWellness Center. Dr. Boham lectures on a variety of topics, including Women's Health and Breast Cancer Prevention, insulin resistance, heart health, weight control and allergies. She is on the faculty for the Institute for Functional Medicine. This episode is brought to you by BIOptimizers. Head to bioptimizers.com/hyman and use code HYMAN to save 15%. Full-length episodes can be found here:Why Most Everything We Were Told About Dairy Is Wrong Is It Okay To Eat Cheese And What Types Of Dairy Should You Avoid? Is Lactose Intolerance Causing Your Gut Issues?